Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen

Journal of Neuro-Oncology

Volumn 93, Issue 3, 2009, Pages 425-430

  Galldiks, Norbert ^a   Ullrich, R ^b   Schroeter, M ^a   Fink, G R ^a   Kracht, L W ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Experimental glioma therapy; L methyl (11)C methionine PET; Platelet derived growth factor (PDGF) receptor; Tyrosine kinase inhibitor

Indexed keywords

[METHYL (11) C]METHIONINE; CONTRAST MEDIUM; HYDROXYUREA; IMATINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CASE REPORT; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; EXPERIMENTAL THERAPY; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; MAINTENANCE THERAPY; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; REOPERATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; GLIOBLASTOMA; HUMANS; HYDROXYUREA; MALE; NEUROSURGICAL PROCEDURES; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES;

EID: 67349272776     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9790-3     Document Type: Article

References (26)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
2. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572-2578
3. Apperley JF, Gardembas M, Melo JV et al (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347(7):481-487. doi: 10.1056/NEJMoa020150
4. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472-480. doi: 10.1056/NEJMoa020461
5. Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645-652. doi: 10.1056/NEJMoa011573
6. Fleming TP, Saxena A, Clark WC et al (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52(16):4550-4553
7. Kilic T, Alberta JA, Zdunek PR et al (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60(18):5143-5150
8. Boruban C, Yavas O, Altundag O, Altundag MB, Altundag K (2005) Imatinib may be useful in the management of patients with glioblastoma. Med Hypotheses 65(6):1205-1206. doi: 10.1016/j.mehy.2005.04.004
9. Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08. Clin Cancer Res 12(16):4899-4907. doi: 10.1158/ 1078-0432.CCR-06-0773
10. Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series. Ann Oncol 16(10):1702-1708. doi: 10.1093/annonc/mdi317
11. Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23(36):9359-9368. doi: 10.1200/JCO.2005.03.2185
12. Kaschten B, Stevenaert A, Sadzot B et al (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39(5):778-785
13. Nuutinen J, Sonninen P, Lehikoinen P et al (2000) Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48(1):43-52. doi: 10.1016/S0360-3016(00)00604-0
14. Würker M, Herholz K, Voges J et al (1996) Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 23(5):583-586
15. Voges J, Herholz K, Holzer T et al (1997) 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: A tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotact Funct Neurosurg 69(1-4 Pt 2):129-135. doi: 10.1159/000099864
16. Shintani S, Tsuruoka S, Shiigai T (2000) Serial positron emission tomography (PET) in gliomatosis cerebri treated with radiotherapy: A case report. J Neurol Sci 173(1):25-31. doi: 10.1016/ S0022-510X(99)00296-8
17. Galldiks N, Kracht LW, Burghaus L et al (2006) Use of (11)C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 33(5):516-524. doi: 10.1007/ s00259-005-0002-5
18. Herholz K, Kracht LW, Heiss WD (2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13(3):269-271. doi: 10.1177/1051228403013003012
19. Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50(5):1316-1322
20. Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M (1990) Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31(5):417-429
21. Kracht LW, Miletic H, Busch S et al (2004) Delineation of brain tumor extent with [11C] l -methionine positron emission tomography: Local comparison with stereotactic histopathology. Clin Cancer Res 10(21):7163-7170. doi: 10.1158/1078-0432.CCR-04-0262
22. Pauleit D, Floeth F, Hamacher K et al (2005) O-(2-[18F]fluoroethyl)-L -tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128(Pt 3):678-687. doi: 10.1093/brain/awh399
23. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H (1997) Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, l-methionine and thymidine. J Nucl Med 38(2):280-287
24. Sonoda Y, Kumabe T, Takahashi T, Shirane R, Yoshimoto T (1998) Clinical usefulness of 11C-MET PET and 201T1 SPECT for differentiation of recurrent glioma from radiation necrosis. Neurol Med Chir (Tokyo) 38(6):342-347. doi: 10.2176/nmc.38.342 (discussion 347-348)
25. Bustany P, Chatel M, Derlon JM et al (1986) Brain tumor protein synthesis and histological grades: A study by positron emission tomography (PET) with C11-L-Methionine. J Neurooncol 3(4):397-404. doi: 10.1007/BF00165590
26. Berger G, Maziere M, Knipper R, Prenant C, Comar D (1979) Automated synthesis of 11C-labelled radiopharmaceuticals: Imipramine, chlorpromazine, nicotine and methionine. Int J Appl Radiat Isot 30(7):393-399. doi: 10.1016/0020-708X(79)90049-8